CounterX News

CounterX Therapeutics Executes Exclusive Licensing Agreement for Portfolio of Novel Monoclonal Antibody and Vaccine Candidates Targeting Fentanyl and Opioid Overdose

•
March 9, 2026

CounterX Therapeutics Announces Formation of Scientific Advisory Board with Leading Experts in Substance Use Disorders

•
March 2, 2026

CounterX Therapeutics Announces Publication Demonstrating CTRX-101, an Anti-Fentanyl Monoclonal Antibody Therapy, Reverses Fentanyl-Induced Overdose in Preclinical Model

•
October 29, 2025